S&P 500   3,357.57 (+1.79%)
DOW   27,665.39 (+1.81%)
QQQ   276.39 (+1.78%)
AAPL   114.14 (+1.66%)
MSFT   209.36 (+0.74%)
FB   256.82 (+0.78%)
GOOGL   1,460.13 (+1.46%)
AMZN   3,159.81 (+2.09%)
TSLA   420.61 (+3.26%)
NVDA   519.03 (+0.79%)
BABA   276.33 (+1.93%)
CGC   14.29 (+0.85%)
GE   6.24 (+2.13%)
MU   49.13 (-0.02%)
AMD   78.84 (+1.00%)
T   28.52 (+1.71%)
F   6.75 (+3.69%)
ACB   4.84 (-4.16%)
GILD   62.78 (+0.85%)
NFLX   489.36 (+1.34%)
DIS   126.51 (+2.02%)
BAC   24.28 (+3.36%)
BA   166.21 (+6.52%)
S&P 500   3,357.57 (+1.79%)
DOW   27,665.39 (+1.81%)
QQQ   276.39 (+1.78%)
AAPL   114.14 (+1.66%)
MSFT   209.36 (+0.74%)
FB   256.82 (+0.78%)
GOOGL   1,460.13 (+1.46%)
AMZN   3,159.81 (+2.09%)
TSLA   420.61 (+3.26%)
NVDA   519.03 (+0.79%)
BABA   276.33 (+1.93%)
CGC   14.29 (+0.85%)
GE   6.24 (+2.13%)
MU   49.13 (-0.02%)
AMD   78.84 (+1.00%)
T   28.52 (+1.71%)
F   6.75 (+3.69%)
ACB   4.84 (-4.16%)
GILD   62.78 (+0.85%)
NFLX   489.36 (+1.34%)
DIS   126.51 (+2.02%)
BAC   24.28 (+3.36%)
BA   166.21 (+6.52%)
S&P 500   3,357.57 (+1.79%)
DOW   27,665.39 (+1.81%)
QQQ   276.39 (+1.78%)
AAPL   114.14 (+1.66%)
MSFT   209.36 (+0.74%)
FB   256.82 (+0.78%)
GOOGL   1,460.13 (+1.46%)
AMZN   3,159.81 (+2.09%)
TSLA   420.61 (+3.26%)
NVDA   519.03 (+0.79%)
BABA   276.33 (+1.93%)
CGC   14.29 (+0.85%)
GE   6.24 (+2.13%)
MU   49.13 (-0.02%)
AMD   78.84 (+1.00%)
T   28.52 (+1.71%)
F   6.75 (+3.69%)
ACB   4.84 (-4.16%)
GILD   62.78 (+0.85%)
NFLX   489.36 (+1.34%)
DIS   126.51 (+2.02%)
BAC   24.28 (+3.36%)
BA   166.21 (+6.52%)
S&P 500   3,357.57 (+1.79%)
DOW   27,665.39 (+1.81%)
QQQ   276.39 (+1.78%)
AAPL   114.14 (+1.66%)
MSFT   209.36 (+0.74%)
FB   256.82 (+0.78%)
GOOGL   1,460.13 (+1.46%)
AMZN   3,159.81 (+2.09%)
TSLA   420.61 (+3.26%)
NVDA   519.03 (+0.79%)
BABA   276.33 (+1.93%)
CGC   14.29 (+0.85%)
GE   6.24 (+2.13%)
MU   49.13 (-0.02%)
AMD   78.84 (+1.00%)
T   28.52 (+1.71%)
F   6.75 (+3.69%)
ACB   4.84 (-4.16%)
GILD   62.78 (+0.85%)
NFLX   489.36 (+1.34%)
DIS   126.51 (+2.02%)
BAC   24.28 (+3.36%)
BA   166.21 (+6.52%)
Log in
NYSE:NVS

Novartis Stock Forecast, Price & News

$87.20
+0.09 (+0.10 %)
(As of 09/28/2020 02:51 PM ET)
Add
Compare
Today's Range
$87.00
Now: $87.20
$87.74
50-Day Range
$82.39
MA: $86.76
$91.00
52-Week Range
$69.18
Now: $87.20
$99.84
Volume40,134 shs
Average Volume2.14 million shs
Market Capitalization$199.57 billion
P/E Ratio27.77
Dividend Yield2.31%
Beta0.45
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products. The company's Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapy, metabolism, oncology, ophthalmic, pain, and respiratory areas; and finished dosage form anti-infective. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. The company's Alcon segment offers intraocular lenses and equipment for cataract procedures; equipment, instruments, and devices for vitreoretinal surgeries; surgical equipment and diagnostic devices for refractive surgical procedures; and devices to treat glaucoma. It also provides viscoelastics, surgical solutions, diagnostic ophthalmic products, surgical packs, and other disposable products for cataract and vitreoretinal surgery. In addition, this segment offers contact lenses and ocular health products; over-the-counter ophthalmic products; eye drops for the temporary relief of ocular itching due to allergies; vitamins for ocular health; and iLux Device, a therapeutic device used to treat meibomian gland dysfunction. Novartis AG has collaboration agreements with Xencor; Surface Oncology; Ligand Pharmaceuticals, Inc.; Amgen; University of California, Berkeley; Bristol-Myers Squibb; IBM Watson Health; Allergan plc; Science 37, Inc.; Bill & Melinda Gates Foundation; PEAR Therapeutics; Pfizer; Conatus Pharmaceuticals Inc.; and TRIO. The company was founded in 1895 and is headquartered in Basel, Switzerland.
Read More
Novartis logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.2Community Rank: 2.3Dividend Strength: 2.5Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.52 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone41-61-324-1111

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$47.50 billion
Cash Flow$7.65 per share
Book Value$24.53 per share

Profitability

Net Income$11.73 billion

Miscellaneous

Employees103,914
Outstanding Shares2,288,700,000
Market Cap$199.57 billion
Next Earnings Date10/27/2020 (Estimated)
OptionableOptionable
$87.20
+0.09 (+0.10 %)
(As of 09/28/2020 02:51 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NVS News and Ratings via Email

Sign-up to receive the latest news and ratings for NVS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Novartis (NYSE:NVS) Frequently Asked Questions

How has Novartis' stock been impacted by Coronavirus (COVID-19)?

Novartis' stock was trading at $82.14 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NVS shares have increased by 6.2% and is now trading at $87.20.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Novartis?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 2 sell ratings, 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Novartis
.

When is Novartis' next earnings date?

Novartis is scheduled to release its next quarterly earnings announcement on Tuesday, October 27th 2020.
View our earnings forecast for Novartis
.

How were Novartis' earnings last quarter?

Novartis AG (NYSE:NVS) released its quarterly earnings data on Tuesday, July, 21st. The company reported $1.36 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.31 by $0.05. The company earned $11.35 billion during the quarter, compared to the consensus estimate of $11.77 billion. Novartis had a return on equity of 24.14% and a net margin of 14.96%. The business's revenue for the quarter was down 3.5% on a year-over-year basis. During the same period last year, the company earned $1.34 earnings per share.
View Novartis' earnings history
.

How often does Novartis pay dividends? What is the dividend yield for Novartis?

Novartis declared an annual dividend on Monday, February 3rd. Investors of record on Wednesday, March 4th will be given a dividend of $3.0425 per share on Thursday, March 12th. This represents a dividend yield of 2%. The ex-dividend date is Tuesday, March 3rd. This is an increase from Novartis's previous annual dividend of $2.86.
View Novartis' dividend history
.

What price target have analysts set for NVS?

9 equities research analysts have issued 1 year price objectives for Novartis' stock. Their forecasts range from $100.00 to $116.00. On average, they expect Novartis' share price to reach $108.00 in the next twelve months. This suggests a possible upside of 23.9% from the stock's current price.
View analysts' price targets for Novartis
.

Are investors shorting Novartis?

Novartis saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 2,470,000 shares, an increase of 14.9% from the August 31st total of 2,150,000 shares. Based on an average daily trading volume, of 1,680,000 shares, the days-to-cover ratio is currently 1.5 days. Currently, 0.1% of the company's shares are short sold.
View Novartis' Short Interest
.

Who are some of Novartis' key competitors?

What other stocks do shareholders of Novartis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novartis investors own include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), AT&T (T), Walt Disney (DIS), Gilead Sciences (GILD), Cisco Systems (CSCO), Merck & Co., Inc. (MRK) and NVIDIA (NVDA).

Who are Novartis' key executives?

Novartis' management team includes the following people:
  • Dr. Vasant Narasimhan, Chief Exec. Officer (Age 43)
  • Mr. Harry Kirsch, Chief Financial Officer (Age 54)
  • Mr. Steffen Lang, Global Head of Technical Operations (Age 52)
  • Ms. Shannon Thyme Klinger, Group Gen. Counsel (Age 48)
  • Dr. Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer (Age 51)

What is Novartis' stock symbol?

Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."

Who are Novartis' major shareholders?

Novartis' stock is owned by a number of retail and institutional investors. Top institutional investors include Fisher Asset Management LLC (0.39%), Bank of America Corp DE (0.37%), Charles Schwab Investment Management Inc. (0.22%), Neuberger Berman Group LLC (0.11%), Schafer Cullen Capital Management Inc (0.10%) and Manning & Napier Group LLC (0.09%).

Which institutional investors are selling Novartis stock?

NVS stock was sold by a variety of institutional investors in the last quarter, including Fort Washington Investment Advisors Inc. OH, FMR LLC, Sei Investments Co., Rockefeller Capital Management L.P., Bank of America Corp DE, Charles Schwab Investment Management Inc., Macquarie Group Ltd., and Schafer Cullen Capital Management Inc.

Which institutional investors are buying Novartis stock?

NVS stock was acquired by a variety of institutional investors in the last quarter, including Neuberger Berman Group LLC, TCTC Holdings LLC, Fisher Asset Management LLC, Clark Capital Management Group Inc., Envestnet Asset Management Inc., Scotia Capital Inc., Canada Pension Plan Investment Board, and Live Oak Private Wealth LLC.

How do I buy shares of Novartis?

Shares of NVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Novartis' stock price today?

One share of NVS stock can currently be purchased for approximately $87.20.

How big of a company is Novartis?

Novartis has a market capitalization of $199.57 billion and generates $47.50 billion in revenue each year. The company earns $11.73 billion in net income (profit) each year or $5.24 on an earnings per share basis. Novartis employs 103,914 workers across the globe.

What is Novartis' official website?

The official website for Novartis is www.novartis.com.

How can I contact Novartis?

Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company can be reached via phone at 41-61-324-1111 or via email at [email protected]

This page was last updated on 9/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.